Wojciech Zareba

Jan 1, 2024 | jacc.org | Ido Goldenberg |Mehmet Aktaş |Wojciech Zareba |David Huang

References1. "Cardiac resynchronization therapy reduces ventricular arrhythmias in primary but not secondary prophylactic implantable cardioverter defibrillator patients: insight from the Resynchronization in Ambulatory Heart Failure Trial". Circ Arrhythm Electrophysiol . 2017;10:3: e004875. 2. "Cardiac-resynchronization therapy for the prevention of heart-failure events". N Engl J Med . 2009;361:1329-1338. 3. "Cardiac-resynchronization therapy for mild-to-moderate heart failure". N Engl J Med .

Mar 30, 2023 | frontiersin.org | Gen-Min Lin |Wojciech Zareba |Samuel T. Savitz

Introduction Implantable cardioverter-defibrillator (ICD) placement is an established interventional therapy for primary prevention of sudden cardiac death (SCD) in patients with heart failure with reduced ejection fraction (HFrEF) (1). Heart Failure (HF) is more common among older (≥65 years) populations and is projected to affect >8 million adults in the United States by 2030 as the population ages (2). Both non-cardiovascular (CV) and CV hospitalizations are common among HF patients (2).